A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients.
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2015
At a glance
- Drugs Refametinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
- 08 Jul 2011 Planned end date changed from Jun 2011 to Dec 2011 as reported by ClinicalTrials.gov.
- 19 May 2011 Status changed from active, no longer recruiting to completed.
- 18 May 2011 Results will be presented at ASCO 2011, according to a Bayer Healthcare media release.